Stocktoria
Chemomab Therapeutics Ltd. CMMB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-08-14
Chemomab Therapeutics Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $5.8M | $11.3M | $18.4M | $17.0M | $6.3M |
| Operating income | -$112.0M | -$103.0M | — | — | — |
| Income tax | $0 | $0 | $0 | -$534,000 | $0 |
| Net income | -$9.0M | -$13.9M | -$24.2M | -$27.6M | -$12.5M |
| EPS (diluted) | $0.02 | $0.04 | $0.10 | $0.12 | $0.06 |
| Operating cash flow | -$11.1M | -$15.4M | -$23.6M | -$20.4M | -$12.4M |
| Free cash flow | -$11.1M | -$15.4M | -$23.6M | -$20.4M | -$12.6M |
| Cash & equivalents | $7.6M | $6.1M | $9.3M | $13.5M | $15.2M |
| Total assets | $13.8M | $17.0M | $22.2M | $43.1M | $64.4M |
| Total liabilities | $1.5M | $3.4M | $5.2M | $6.8M | $2.9M |
| Shareholders' equity | $12.3M | $13.5M | $17.0M | $36.2M | $61.5M |
Source: SEC EDGAR filings · CIK 0001534248 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.